ACTA1 and metabolic dysfunction-associated steatohepatitis: In a mouse model of NASH and fibrosis, resmetirom improved MAFLD activity score and decreased hepatic fibrosis by lowering the content of αSMA and down-regulating genes involved in fibrogenesis such as collagen 1α1, lysyl oxidase-like 2, and hydroxysteroid 17-β dehydrogenase 13 [176].